Resolvins discovery (early 2000s)
Charles Serhan's lab at Harvard found lipid molecules called resolvins that actively shut down inflammation. This showed the body resolves inflammation through active chemical signals rather than passive decay.
Resolvins became a research field and led to synthetic resolvin analogs in development.
Established the concept of pro-resolving mediators, the intellectual foundation the UCL study builds on.
Epoxy-oxylipins belong to the same family of lipid mediators and add a new, druggable target to the resolution toolkit.
